Ampio Pharma slides as new study likely needed for pain drug

Ampio Pharmaceuticals

21/04/2022 11:06

** Drug developer's shares  AMPE.A  fall 33.9% to 22 cents
premarket, the top percentage loser across U.S. exchanges 
    ** Stock set for a record low if losses hold in regular
trading
    ** Co's CEO says the best path forward for the company's
drug to treat pain due to osteoarthritis in the knee is likely
conducting a new late-stage trial  urn:newsml:reuters.com:*:nPn6P7nxRa
    ** Says U.S. FDA did not agree with co's proposal to
consider an earlier trial of the drug, Ampion, as basis for
approval
    ** Up to Wednesday's close, stock had fallen ~40% YTD

 (Reporting by Manas Mishra)
 ((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manaswrites15))